Related Experiment Video
Updated: Dec 25, 2025

Author Spotlight: A Novel 3D-Printed Titanium Implant for Minimally Invasive Treatment of Hip Dysplasia in Young Dogs
Published on: April 19, 2024
Abstract:
The Food Safety Commission of Japan (FSCJ) conducted a risk assessment of methylprednisolone (CAS No. 83-43-2), a steroidal anti-inflammatory agent, using the evaluation reports from EMA (EMEA) and other related documents. Although no genotoxicty study in vivo was available, all the genotoxicity studies in vitro were negative. In addition, prednisolone, a structural analogue of methylprednisolone, is judged to have no genotoxicity relevant to human health. Thus, methylprednisolone is considered to have no genotoxicity relevant to human health. Therefore, FSCJ concluded it possible to specify an acceptable daily intake (ADI) of methylprednisolone. Major adverse effects of methylprednisolone observed are reduced counts of leukocyte, thymic atrophy, decreased weights of spleen, and glycogen accumulation in hepatocyte. FSCJ specified an ADI of 0.0003 mg/kg bw/day for methylprednisolone applying a safety factor of 1,000 to the LOAEL of 0.3 mg/kg bw/day in the 63-day subacute toxicity study in rats.
Insights
The Food Safety Commission of Japan assessed methylprednisolone, finding no genotoxicity concerns. An acceptable daily intake (ADI) was established at 0.0003 mg/kg bw/day for this anti-inflammatory steroid.
Area of Science:
- Pharmacology and Toxicology
- Food Safety Risk Assessment
Background:
- Methylprednisolone is a steroidal anti-inflammatory agent.
- Risk assessment utilized EMA (EMEA) reports and other relevant documents.
Purpose of the Study:
- To conduct a comprehensive risk assessment of methylprednisolone (CAS No. 83-43-2).
- To determine an acceptable daily intake (ADI) for methylprednisolone.
Main Methods:
- Evaluation of available genotoxicity studies (in vitro and in vivo).
- Assessment of adverse effects from toxicity studies.
- Application of safety factors to establish ADI based on LOAEL.
Main Results:
- All available in vitro genotoxicity studies for methylprednisolone were negative.
- Methylprednisolone is considered to have no genotoxicity relevant to human health.
- Identified adverse effects include reduced leukocyte counts, thymic atrophy, decreased spleen weights, and hepatocyte glycogen accumulation.
Conclusions:
- The Food Safety Commission of Japan (FSCJ) concluded that an ADI for methylprednisolone could be specified.
- An ADI of 0.0003 mg/kg bw/day was established using a safety factor of 1,000 on the LOAEL from a rat study.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Pharmaceutical Equivalents
Clinically Relevant Drug Product Specifications: Methods of Establishment
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...

